Vaginal Estriol in Multiple Sclerosis

Completed · Phase 2/Phase 3

Conditions studied: Multiple Sclerosis, Neurogenic Bladder

In brief

Study to evaluate the efficiency of vaginal estriol, as a treatment for urogenital symptoms in female patients with RRMS. The secondary objective is to evaluate the potential role of vaginal estriol in re-myelination in RRMS patients.

Key facts

Study ID

NCT03774407

Run by

Texas Tech University Health Sciences Center

People needed

21

Starts

2019-06-20

Expected to finish

2020-11-29

Last updated by the study team

2022-09-21

Who can join

Age: 40 and older, up to 65. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Female patients with RRMS over the age of 40 to 65.
• Being prescribed vaginal estriol to treat their urogenital symptoms such as frequency, urgency, incontinence and frequent urinary tract infections.
• Patients that had underwent chemical or surgical hysterectomy.
• Patients will continue their current disease modifying agent for MS during the trial.

You may not qualify if…

• Patients with history of breast cancer, uterine or ovarian cancer.
• Patients with progressive multiple sclerosis
• Patients who are unable to undergo an MRI
• Males
• Patient is already on vaginal or oral or transdermal estrogens
• Pregnant or breast-feeding patients
• Patient taking sex hormones eg testosterone for libido
• Patients taking DHEA or OTC related products that could influence the hormonal milieu.
• Patient with prolapse uterus or conditions that would impact on transvaginal absorption of estriol

Where it is running

• Texas Tech University Health Sciences Center — Lubbock, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.